High-throughput screening of a diversity collection using biodefense category A and B priority pathogens.

ABSTRACT: One of the objectives of the National Institutes of Allergy and Infectious Diseases (NIAID) Biodefense Program is to identify or develop broad-spectrum antimicrobials for use against bioterrorism pathogens and emerging infectious agents. As a part of that program, our institution has screened the 10 000-compound MyriaScreen Diversity Collection of high-purity druglike compounds against three NIAID category A and one category B priority pathogens in an effort to identify potential compound classes for further drug development. The effective use of a Clinical and Laboratory Standards Institute-based high-throughput screening (HTS) 96-well-based format allowed for the identification of 49 compounds that had in vitro activity against all four pathogens with minimum inhibitory concentration val

SUBMITTER: Barrow EW 

PROVIDER: S-EPMC3700734 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature